FDA Updates SMA Treatment Dosing - Poll - MDSpire

FDA Updates SMA Treatment Dosing

A higher-dose nusinersen regimen for spinal muscular atrophy demonstrated statistically significant motor function improvement in treatment-naïve infants in the DEVOTE trial with a safety profile consistent with prior dosing.

  • By

  • Kathryn Wighton

  • March 30, 2026

  • 2 min

Share

Original Source(s)

FDA Updates SMA Treatment Dosing

  • by Kathryn Wighton

  • March 30, 2026

Related Content

Top 10 Evidence-Based Essentials in Neurology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice.

Development and validation of a clinical nomogram for predicting 30-day in-hospital mortality in children with moderate-to-severe traumatic brain injury

Handwriting Kinematics Differentiate Cognitive Impairment

“Diagnostic differentiation emerged only under tasks imposing higher cognitive-motor demands.”